Viking Therapeutics (VKTX) Operating Expenses (2014 - 2026)

Viking Therapeutics has reported Operating Expenses for 13 years, with the latest figure at $132.6 million in Q2 2026.

• Quarterly Operating Expenses rose 77.81% year-over-year to $132.6 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $560.0 million (up 163.12% YoY) and the FY2025 annual result came in at $393.3 million, up 160.63% from the prior year.
• Operating Expenses declined to $132.6 million in Q2 2026 per VKTX's latest filing, from $164.1 million in the prior quarter.
• Over five years, Operating Expenses peaked at $164.7 million in Q4 2025 and troughed at $16.2 million in Q3 2022.
• A 5-year average of $56.2 million and a median of $34.1 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses gained 13.45% in 2022, then soared 256.28% in 2025.
• Over 5 years, Operating Expenses stood at $20.3 million in 2022, then jumped by 44.38% to $29.3 million in 2023, then soared by 57.89% to $46.2 million in 2024, then jumped by 256.28% to $164.7 million in 2025, then dropped by 19.51% to $132.6 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $132.6 million, $164.1 million, and $164.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.